MLH1 Protein Qualitative Test Kit - Vietnam Registration 2403708ĐKLH/BYT-HTTB
Access comprehensive regulatory information for MLH1 Protein Qualitative Test Kit in Vietnam's medical device market through Pure Global AI's free database. This Risk Class TBYT Loại C medical device is registered under number 2403708ĐKLH/BYT-HTTB and manufactured by Ventana Medical Systems, Inc.. The authorized representative in Vietnam is CÔNG TY TNHH ROCHE VIỆT NAM.
This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 300,000+ Vietnamese medical device registrations, helping global MedTech companies navigate Vietnam MOH regulations, identify competitors, and discover partnership opportunities efficiently.
Device Details
Registration Details
2403708ĐKLH/BYT-HTTB
000.00.04.G18-230724-0005
VENTANA anti-MLH1 (M1) Mouse Monoclonal Primary Antibody
09605584001
Technical Details
VENTANA anti-MLH1 (M1) Mouse Monoclonal Primary Antibody (VENTANA anti-MLH1 (M1)) is used to detect the presence of the MLH1 protein in formalin-fixed, paraffin-embedded tissue sections. The VENTANA anti-MLH1 (M1) Mouse Monoclonal Primary Antibody is available as a ready-to-use reagent on the BenchMark IHC/ISH platform, along with the OptiView DAB IHC Detection Kit and supporting reagents. VENTANA anti-MLH1 (M1) Mouse Monoclonal Primary Antibody is a component of the VENTANA MMR IHC Panel (the VENTANA MMR Histology Immunoassay Panel), which includes VENTANA anti-PMS2 (A16-4) Mouse Monoclonal Primary Antibody, VENTANA anti-MSH2 (G219-1129) Mouse Monoclonal Primary Antibody, VENTANA anti-MSH6 (SP93) Rabbit Monoclonal Primary Antibody, and VENTANA anti-BRAF V600E (VE1) Mouse Monoclonal Primary Antibody. The VENTANA MMR IHC Panel is indicated for the detection of mismatch repair deficient protein, a test to identify individuals at risk for Lynch syndrome in patients diagnosed with colorectal cancer (CRC), and in combination with BRAF V600E status, aids in differentiating between sporadic colorectal cancer and colorectal cancer that may be due to Lynch syndrome when MLH1 protein expression is absent. This product must be interpreted by a qualified pathologist in conjunction with histology testing, relevant clinical information, and appropriate control material (positive control). This antibody is intended for in vitro diagnostic use (IVD).
Dates and Status
Nov 19, 2024

